Zimbabwe has rejected a major American healthcare agreement worth $367m (272 million pounds) over five years over the United States' demand for sensitive information.
The decision became public after a government memo from December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the agreement was "skewed".
An official spokesman has since clarified that the US was seeking genetic material for research and commercial gain while was not willing to share the resulting advantages from any future treatments.
"We are forced to start the challenging and unfortunate task of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had provided over $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for more dialogue to find a agreement agreeable to all parties so the country's vital HIV treatment initiative can proceed.
Broader Implications
Zimbabwe's decision comes after a comparable case in Kenya, where a high court halted a similar health funding agreement following concerns were raised about the security of citizens' medical information.
After resuming office last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump claimed its expenditure was "inefficient" and his administration was seeking direct bilateral agreements to enhance openness and accountability.
As per statements, 16 African countries have to date agreed to these new agreements, constituting over $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment through American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to surrender its genetic material and health information over an extended period, without any equivalent promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," Mangwana explained.
"Put simply, our country would supply the basic resources for scientific discovery with no assurance that the final treatments would be accessible to our citizens if a future health crisis emerge."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one deals were disrupting frameworks already established through the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential pandemics.
"This mechanism is intended to guarantee that when a nation provides its samples, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
These objections regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We encourage ongoing dialogue with our American counterparts on how subsequent collaboration might be designed in a manner that respects the sovereignty and interests of each country."
Health Experts Response
A leading public health body expressed it acknowledged the government's concerns, but urged that talks should continue since much of the nation's HIV programmes were funded by international support.
"In cases where technical issues exist, including those relating to data governance or implementation frameworks, these can frequently be addressed through technical clarification and negotiated safeguards," it commented.
The halted deal highlights the complex tensions between receiving vital foreign assistance and protecting national sovereignty in an increasingly data-driven world.